Gene
ARID1A
ARID1A is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (42), Actionable biomarkers (5), Trial mentions (52), and 7 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
2 more sections with rows · 2 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention ARID1A. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 12 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 4 of 8,738 | 0.05% | not measured | |
| 2025 | 4 of 8,875 | 0.05% | not measured | |
| 2024 | 3 of 8,597 | 0.03% | not measured | |
| 2023 | 3 of 8,275 | 0.04% | 41 of 11,460 | 0.36% |
| 2022 | 7 of 8,285 | 0.08% | 45 of 13,598 | 0.33% |
| 2021 | 8 of 8,692 | 0.09% | 42 of 15,045 | 0.28% |
| 2020 | 6 of 7,640 | 0.08% | 42 of 14,459 | 0.29% |
| 2019 | 8 of 7,300 | 0.11% | 36 of 12,159 | 0.30% |
| 2018 | 2 of 6,927 | 0.03% | 35 of 11,854 | 0.30% |
| 2017 | 1 of 6,558 | 0.02% | 28 of 11,595 | 0.24% |
Showing 10 of 37 years.
Assay-provider ledger (42)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Foundation Medicine | Diagnostic provider | Clinical validationAnalytical validation | 4 | August 01, 2026 |
| Olympus Corporation of Americas | Reagent supplier | Clinical validationAnalytical validation | 1 | August 01, 2026 |
| THERMO FISHER SCIENTIFIC (Click-iT EdU kit, TaqMan Low-Density Array reagents, ExpressionSuite/DataAssist software) | Reagent supplier | Clinical validationAnalytical validation | 3 | August 01, 2026 |
| University of Pittsburgh Medical Center (UPMC) Molecular & Genomics Pathology (MGP) laboratory | Not a company | Clinical validationAnalytical validation | 1 | August 01, 2026 |
| AB Applied Biosystems | Reagent supplier | Clinical validationAnalytical validation | 3 | July 01, 2025 |
Showing 5 of 42 assay-provider companies.
Actionable biomarkers (5)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| ARID1A amplification + ANXA1 overexpression | TRASTUZUMAB | responsive | breast adenocarcinoma | Cancer Genome Interpreter |
| ARID1A oncogenic mutation + ANXA1 overexpression | TRASTUZUMAB | responsive | breast adenocarcinoma | Cancer Genome Interpreter |
| ARID1A oncogenic mutation | Ezh2 Inhibitors | response-associated | ovarian carcinoma | Cancer Genome Interpreter |
| ARID1A oncogenic mutation | Atr Inhibitors | response-associated | No disease recorded | Cancer Genome Interpreter |
| ARID1A oncogenic mutation | Parp Inhibitors | response-associated | No disease recorded | Cancer Genome Interpreter |
Trial mentions (52)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT06790602 | Trial eligibility (AACT) |
| NCT03568656 | Trial eligibility (AACT) |
| NCT05690035 | Trial eligibility (AACT) |
| NCT04104776 | Trial eligibility (AACT) |
| NCT02286687 | Trial eligibility (AACT) |
Showing 5 of 52 trial mentions.
Target-disease associations (702)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 3-hydroxybutyrate measurement | measurement | GWAS credible sets |
| Abnormality of the skeletal system | phenotype | GWAS credible sets |
| Absent speech | phenotype | Variant curation (ClinVar / EVA) |
| Adenofibroma | cancer or benign tumor | Literature (Europe PMC) |
| Adenosquamous Carcinoma | cancer or benign tumor | Literature (Europe PMC) |
Showing 5 of 702 associations.
Vendor sourcing (214)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | Stop-gained (nonsense): predicted to result in a loss or disruption of normal protein function through nonsense-mediated decay (NMD) or protein truncation. M... | View ClinVar record SCV002012014.1 |
| ARUP Laboratories (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | No supporting text recorded; see the citation. | View ClinVar record SCV004565323.1 |
| Academic and Community Cancer Research United | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : * Age \>= 18 years * Histological or cytological documentation of metastatic adenocarcinoma of the biliary tract * Patients with previously identified gen... | View trial NCT04042831 |
| Academic and Community Cancer Research United | Trial sponsor | Mentioned in trial textTrial free-text mention | ARID1A | View trial NCT04042831 |
| Acrotech Biopharma Inc. (United States) | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : * Male or female subject aged ≥ 18 years. * Histologically confirmed solid tumor with metastatic disease or with unresectable, locally advanced disease * ... | View trial NCT04315155 |
Showing 5 of 214 sourcing records.
Trial-cited literature (364)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Cancer of the ovary, fallopian tube, and peritoneum: 2025 update. | International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics | 2025 | 27 |
| Phase II Study of Niraparib in Patients With Advanced Melanoma With Homologous Recombination Pathway Gene Mutations. | JCO precision oncology | 2025 | 9 |
| Gene actionability according to the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) in No Specific Molecular Profile (NSMP) endometrial cancer. | ESMO open | 2025 | 4 |
| Tumor gene expression signatures associated with outcome in large B-cell lymphoma treated with CD19-directed CAR T-cell therapy (axicabtagene ciloleucel). | Frontiers in oncology | 2025 | 3 |
| Clinical and molecular characteristics of paediatric mature B-cell acute lymphocytic leukaemia and non-Hodgkin lymphoma with bone marrow involvement: A joint study between the CCCG leukaemia and lymphoma groups. | British journal of haematology | 2025 | 2 |
Showing 5 of 364 papers.
Protein variant mentions (60)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A167V | 1 | 2015 | PMID 25741868 |
| p.A1927P | 1 | 2015 | PMID 25741868 |
| p.A2182P | 1 | 2015 | PMID 25741868 |
| p.A3169V | 1 | 2018 | PMID 29349598 |
| p.D1050Y | 1 | 2015 | PMID 25741868 |
Showing 5 of 60 variants.
Human sample screening reference (1)
Shown in this order: alphabetical by variant.
| Variant | GDC project | Disease / site | Affected cases | Profiled cases | Observed frequency | 95% interval |
|---|---|---|---|---|---|---|
| p.G1139V | TARGET-NBL | Not Applicable; Neuroepitheliomatous Neoplasms; Other endocrine glands and related structures; Stomach; Meninges; Skin; Unknown; Bones, joints and articular cartilage of limbs; Connective, subcutaneous and other soft tissues; Lymph nodes; Hematopoietic and reticuloendothelial systems; Renal pelvis; Bones, joints and articular cartilage of other and unspecified sites; Retroperitoneum and peritoneum; Adrenal gland; Liver and intrahepatic bile ducts; Other and ill-defined sites; Spinal cord, cranial nerves, and other parts of central nervous system; Peripheral nerves and autonomic nervous system; Heart, mediastinum, and pleura; Uterus, NOS; Kidney | 1 | 696 | 0.14% | 0.03% to 0.81% |
Literature-extracted relations (59)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| FULVESTRANT | Chemical | associate |
ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer. | 2020 |
| Endometrial Neoplasms | Disease | associate |
Gene actionability according to the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) in No Specific Molecular Profile (NSMP) endometrial cancer. | 2025 |
| Neoplasms | Disease | associate |
Phase II Study of Niraparib in Patients With Advanced Melanoma With Homologous Recombination Pathway Gene Mutations. | 2025 |
| Angina, Stable | Disease | associate |
Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response Pathway-Deficient Neoplasms. | 2024 |
| Neoplasms | Disease | associate |
Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation. | 2024 |
Showing 5 of 59 relation assertions.
Organizations publishing (411)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | Hospital | 47 | 2013 to 2024 |
| Dana-Farber Cancer Institute | Other | 26 | 2012 to 2023 |
| The University of Texas System | Academic | 26 | 2017 to 2025 |
| Government of the United States of America | Government | 20 | 2014 to 2023 |
| Harvard Medical School | Academic | 18 | 2012 to 2024 |
Showing 5 of 411 organizations.
Where ARID1A appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- infectious disease
- integumentary system disease
- measurement
- medical procedure
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- reproductive system or breast disease
- respiratory or thoracic disease
617 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions and fda biomarker qualification projects.